| Methods | ALLOCATION CONCEALMENT: unclear BLINDING: not blind | |
| Participants | DIAGNOSIS: DSM‐IV panic disorder (% agoraphobic unspecified) AGE: mean=31.4 to 31.7 years SEX: men and women HISTORY: ‐ PSYCHIATRIC COMORBIDITY: No comorbidity was allowed. MEDICAL COMORBIDITY: ‐ | |
| Interventions | ACUTE PHASE: 9 weeks 1. fluvoxamine (mean=64 mg/d) + CBT (9 weekly sessions) 2. fluvoxamine alone (mean=154 mg/d) 3. CBT alone ACUTE PHASE CO‐INTERVENTION: not specified MAINTENANCE: None. FOLLOW‐UP: None. |
|
| Outcomes | RESPONSE: >=50% reduction in panic frequency [imputed from mean&SD] REMISSION: ‐ GLOBAL: ‐ PANIC ATTACK: panic frequency AGORAPHOBIA: ‐ GENERAL ANXIETY: HAM‐A, BAI DEPRESSION: HAM‐D, BDI FUNCTIONING: ‐ | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.